Skip to contentSkip to content

LONGEVITY GUIDE

Where should you begin with healthy ageing?

A more energetic present, a healthy weight and a stronger future. Start with the question that challenges you most in everyday life; discover what you can assess, which measurements are meaningful and where the scientific evidence is strong.

Dr. Halil Ertürk38 min readUpdated: 20 August 2026
Dr. Halil Ertürk
Contents

From Dr. Halil Ertürk

This guide was prepared to help you identify the right health priorities amid the information overload.

When longevity is discussed, we often encounter a long list of tests, a new supplement or a single “biological age” score. Yet healthy ageing cannot be reduced to any one of these. I felt the need for this guide to connect scientific knowledge with your everyday decisions and to explain, in a clear and measured order, what truly matters.

The aim is not simply to live longer. It is to preserve your strength, mobility, mental clarity, independence and vitality as much as possible throughout your life. This guide was prepared for adults who want to manage their future health more consciously. You can read the sections in order or use the menu on the left to go to the topic that interests you. Use what you read not as a personal prescription, but as a roadmap that strengthens the assessment you undertake with your physician.

CHAPTER 1

Understanding Longevity Correctly

Healthy ageing is not only about how many years you will live. Being able to move and preserving your cognitive function and independence are also part of the goal. Discover which outcomes matter, rather than focusing on a single rejuvenation number.

Adding function to your years

Adding function to your yearsLifespan describes the years lived; healthspan describes the years in which health and function are maintained. Goals include preserving movement, cognitive function, independence and quality of life.LifespanYears livedHealthspanYears with health and function maintainedMovementCognitivefunctionIndependenceQualityof life
How you spend those years matters as much as living longer. This diagram does not predict individual lifespan or treatment outcomes.
Text description of the visual

Lifespan describes the years lived; healthspan describes the years in which health and function are maintained. Goals include preserving movement, cognitive function, independence and quality of life.

To discuss healthy ageing accurately, we first need to distinguish lifespan from healthspan. This section focuses on function, independence and quality of life rather than a single number or a promise of “staying young”.

1.1

What is longevity?

The quality of the years lived in good health matters as much as lifespan.

Longevity is not merely an effort to extend the time between birth and death. Lifespan describes how many years we live; healthspan describes how much of that time we spend with a low burden of disease, active, independent and mentally productive. This second concept, known in English as “healthspan”, is the central focus of a sound approach to longevity.

Delaying disease is important, but it is not the only goal. Being able to climb stairs, manage everyday tasks without help, and continue learning and participating in social life are also health outcomes. Muscle strength, cardiorespiratory capacity, sleep, cognition and quality of life are therefore assessed alongside laboratory values. Healthy ageing aims to add function and meaning to the years, as well as years to the end of life.

1.2

Do we all age at the same rate?

Chronological age may be the same, while biological change differs between individuals and between organs.

Chronological age is the time that has passed on the calendar and cannot be changed. Biological age is a framework that attempts to describe how the body's different systems have changed during that time. Two people of the same age may differ markedly in blood pressure, muscle strength, metabolic health and cognitive capacity. Even within one person, the heart, muscles and immune system do not necessarily age at the same rate.

Genetic predisposition matters, but it does not determine everything. Smoking, movement, nutrition, sleep, environmental exposures, education, social circumstances and disease management influence the course over the years. Rather than deriving a definitive “age” from a single test, it is therefore more meaningful to examine changes in several clinical and functional indicators over time.

1.3

The true goal of healthy ageing

Identifying risks early and developing the capacity to preserve independence in later years.

The first goal of healthy ageing is to identify modifiable risks before disease develops. Family history and living conditions matter alongside areas such as blood pressure, glucose, blood lipids and tobacco use. Risk assessment is undertaken not to create fear, but to determine which step should come first.

The second goal is to preserve and increase capacity. Muscle and bone strength affect falls, cardiorespiratory capacity affects everyday endurance, and brain health affects decision-making and independence. Physical and mental performance should not be viewed solely as sporting outcomes; they are fundamental to managing one's own life at an older age. A good plan considers today's measurable data together with future function.

↑ Back to the chapters
CHAPTER 2

When rest is not enough: understanding your fatigue

Persistent fatigue should not simply be accepted as a natural consequence of a busy life or ageing. The first step is not to choose a supplement, but to understand when the problem began and how it affects your everyday life.

The right questions about fatigue

The right questions about fatigueA fatigue assessment considers duration, sleep, the relationship to exertion, medicines and accompanying symptoms together. The steps are describing the concern, clinical assessment, targeted investigations if needed, and a personal plan.When did it start?How is your sleep?Have medicines ordaily routines changed?Any othersymptoms?Rest does notrestore my energyHow does exertion affect it?
These questions help you prepare for a consultation; answers do not automatically produce a diagnosis or a test package.
Text description of the visual

A fatigue assessment considers duration, sleep, the relationship to exertion, medicines and accompanying symptoms together. The steps are describing the concern, clinical assessment, targeted investigations if needed, and a personal plan.

The same word, different concerns

What do you mean when you say “I am tired”? Do you feel as if you might fall asleep during the day, struggle to find the energy to do your tasks, or find an activity difficult that used to feel easy? Starting the consultation by explaining this distinction helps clarify the problem. You do not need to diagnose yourself with a single word.

Details that change the assessment

Noting the following information can make the consultation easier:

  • When did it begin? Is it constant or more noticeable at certain times of day?

  • Do you wake feeling rested? Has anyone described snoring or pauses in your breathing during sleep?

  • Have you had a new illness, a change of medication or a change in your daily routine?

  • Do you struggle during exertion, or is there a prolonged worsening afterwards?

  • Is there accompanying unintentional weight loss, bleeding or any other new symptom?

This is not a scoring list. Which questions take priority will depend on your individual history.

Normal tests do not mean your symptoms are unimportant

Some causes are understood through history, examination or sleep assessment rather than blood tests. For example, snoring and daytime sleepiness may warrant assessment for sleep apnoea. Anaemia, blood glucose or thyroid problems may also be investigated in the appropriate clinical context; one symptom does not prove any of them. Rather than ordering the same broad panel for everyone, the investigation that would change the decision should be identified.

The physician's approach

The priority here is not to look for an “energy-boosting product”, but to understand the pattern of the symptoms. When needed, assessment considers medicines, sleep, nutrition, mental health and accompanying illnesses together. The expected benefit and safety of a supplement, and its relationship to medicines being taken, are assessed separately as well.

What could your first step be?

For a few days, keep brief notes on your sleep times, when fatigue is most noticeable, and which everyday tasks have become difficult. This record does not establish a diagnosis; it may help you describe your symptoms more concretely at the consultation. Seek assessment if fatigue has continued for several weeks, has no clear cause, or affects your everyday life.

Take worsening after exertion seriously

If you experience marked, delayed and prolonged worsening after physical or mental effort, describe this specifically. In that situation, continually increasing activity by pushing yourself may not be appropriate. This symptom alone is not a diagnosis of ME/CFS; individual assessment is needed.

Understanding your daily energy is an important part of your healthy ageing plan. However, fatigue alone does not mean you are ageing rapidly or have a vitamin deficiency.

↑ Back to the chapters
CHAPTER 3

Healthy weight management: losing weight, preserving muscle and sustaining progress

The aim of healthy weight management is not simply a lower number on the scales. Assessment should consider fat distribution, muscle strength, metabolic health and the sustainability of your routine together.

Four perspectives beyond the scales

Four perspectives beyond the scalesWeight management assessment may consider waist circumference, strength, function and sustainability alongside weight.WeightOverall changeWaist circumferenceFat distributionStrength and functionWhat you can doSustainabilityMaintaining the routine
Do not judge progress by kilograms alone. These areas do not establish a diagnosis on their own; they are assessed alongside your individual health.
Text description of the visual

Weight management assessment may consider waist circumference, strength, function and sustainability alongside weight.

Why are the scales not enough on their own?

Weight and body mass index are useful starting measurements, but do not provide enough information about muscle quantity and fat distribution by themselves. Waist circumference helps assess central fat accumulation in some people. Results are interpreted alongside age, body build and health. It is also not right to attribute every symptom to weight; any other concern should be assessed separately.

Weight regain is not a test of character

Explaining weight management solely in terms of “being more determined” is incomplete. Genetics, the living environment, sleep, some medicines and health problems may affect the process. When weight returns, it is more meaningful to examine which part of the plan could not be sustained and what support was missing than to blame yourself.

Do not leave muscle strength out of the plan

Lean tissue may also decrease during weight loss. It is therefore important not to track progress only in kilograms, but to consider nutritional adequacy, appropriate exercise and strength together. In a study of adults aged 65 and over with obesity, groups whose weight-loss programme included resistance exercise lost less lean tissue than the group doing aerobic exercise alone. This finding does not guarantee the same outcome or zero muscle loss for everyone.

How can you build a routine that suits you?

A nutrition plan should fit your health, daily life and preferences. Instead of treating extreme restriction alone as a long-term solution, consider nutritional quality and practicality together. Incorporating movement into everyday life and continuing support during weight maintenance are also part of progress.

The physician's approach

Assessment considers not only “how much weight do you want to lose?”, but also what you have tried before, what could not be sustained, and which health problems accompany it. Goals and follow-up measurements are selected accordingly. There is no single ideal weight, diet or follow-up frequency for everyone.

Where do medicines fit into this approach?

Medication is one of the options that may be considered for a suitable person in weight management; it does not replace nutrition, movement and follow-up. Selection and use are based on a physician's assessment. This guide does not recommend an individual medicine or dose.

Do not leave maintenance until the end

It may be useful to discuss these three questions at the outset:

  • Can I sustain the routine I have established during a busy week as well?

  • Which health or functional indicator will we monitor apart from the scales?

  • How will we review the plan if my weight starts to rise again?

Weight maintenance is not a gap after treatment ends; it is an ongoing part of management. The form and duration of support vary between individuals.

The aim is not merely to be lighter, but to establish a routine that supports your daily life and takes care of your muscles and health.

↑ Back to the chapters
CHAPTER 4

Longevity Begins with Measuring Your Health

A good assessment is not about doing more tests. Blood pressure, laboratory tests, body composition and functional measurements answer different questions. Focus on which information would change a decision for you.

From measurement to decision

From measurement to decisionA question, appropriate measurement, clinical context, decision and follow-up form a sequence. Blood pressure is interpreted with measurement conditions and repeated results; biological age is interpreted with the method used and other health indicators.01 · Question02 · Right measurement03 · Clinical context04 · Decision05 · Follow-upReassess the result in context→←
A change in a measurable number does not, by itself, prove improved health or rejuvenation.
Text description of the visual

A question, appropriate measurement, clinical context, decision and follow-up form a sequence. Blood pressure is interpreted with measurement conditions and repeated results; biological age is interpreted with the method used and other health indicators.

Measurement does not mean having more tests. The right question is which measurement will change a decision. This section explains basic risks, body composition, functional capacity and the limitations of biological age tests.

4.1

Do normal test results mean that you are healthy?

A reference range alone is not a personal health target or a risk assessment.

Laboratory reference ranges are generally based on the distribution of results in a broad population. A value within the range does not mean that all of that person's risks are low; a value outside it does not always mean disease either. Age, sex, medicines, sampling conditions and accompanying symptoms affect the result.

A trend is more valuable than a single measurement. Blood glucose rising over the years or declining kidney function may be clinically noteworthy even while still marked “normal”. Tests should be interpreted alongside history, examination, blood pressure, body composition and, when necessary, imaging or functional measurements. The aim is not to chase an ideal number, but to understand the individual's risk and direction of change accurately.

4.2

Assessing basic health risks

Family history, vital signs, metabolic indicators, organ function and appropriate screening are considered together.

The initial assessment begins with a family history of conditions such as early heart disease, diabetes, cancer or fractures. Modifiable risks such as blood pressure, blood glucose, blood lipids, waist circumference and tobacco use are then assessed. Insulin resistance is considered not through one value alone, but together with the clinical situation, glucose trends and body composition.

Liver, kidney and thyroid tests are selected in relation to symptoms and risk. Cancer screening is planned according to age, biological sex, family history and the country's current programmes. Applying the same broad panel to everyone can lead to false-positive results, unnecessary anxiety and additional procedures. Priority goes to assessments whose results will genuinely change a health decision.

4.3

Body composition: what the scales do not show

Weight alone does not provide enough information about muscle, fat distribution or bone.

Scales show total weight; they do not tell us how much of it is muscle, fat, bone or water. Although useful at population level, body mass index may classify a muscular person as overweight or suggest low risk in someone with muscle loss. Waist circumference and intra-abdominal fat provide additional information about metabolic risk.

Muscle mass matters for movement, glucose utilisation and independence; bone mineral density matters for fracture risk. DEXA can provide detailed information on fat, lean tissue and bone density when appropriate, but it is not mandatory for everyone, and the results must be considered in the context of the device and their interpretation. The most meaningful approach evaluates the measurement alongside strength, performance and change over time.

4.4

How are function and performance measured?

Strength, speed, balance, aerobic capacity, sleep and cognition together reflect functional health.

Functional health concerns what we can do in everyday life. Simple measures such as grip strength, chair rises, walking speed and balance provide information about the capacity of the neuromuscular system. Aerobic capacity and VO₂max reflect how well the heart, lungs, circulation and muscles work together; resting heart rate and recovery after exercise may also be useful in context.

In addition to sleep duration, waking refreshed, daytime function and possible symptoms of sleep apnoea should be assessed. Cognitive measurements can establish a baseline for memory, attention and executive function; the learning effect is considered when testing is repeated. A single performance result is not a label of “good” or “bad”. The aim is to establish a safe starting point and monitor change.

4.5

What do biological age tests tell us?

Different biological age methods measure different processes; a single score is not an absolute truth.

Epigenetic clocks generate estimates from DNA methylation patterns, methods such as DunedinPACE estimate the pace of ageing, and clinical algorithms use routine biomarkers. Telomere length and organ-based models address other biological layers. Each method has different data, margins of error and comparison populations; results may not agree with one another.

The fact that a score can be measured does not mean that lowering it makes a person healthier or longer-lived. Its clinical relevance is determined by the method's accuracy, reproducibility, relationship to disease and function, and whether the result changes a decision. Biological age is not a number that delivers a verdict on its own; it is a largely research-oriented indicator that can be interpreted alongside other risk and functional measures, using the same method and considering change over time.

↑ Back to the chapters
CHAPTER 5

The Foundations of Healthy Ageing

Nutrition, movement, sleep, social connections and reducing harmful exposures provide a solid starting point. You do not have to change everything at once. Choose priorities that fit your everyday life and proceed safely.

Choose priorities that fit your daily life.

  • Nutrition
  • Movement
  • Sleep
  • Social connections
  • Reducing harmful exposures
You do not have to change everything at once. Safely build suitable steps into your everyday life.

A strong longevity plan begins not with remarkable products, but with the foundations whose effects are best demonstrated. These areas are not independent of one another: sleep affects appetite and recovery, movement affects glucose control, and social connections affect mental and cognitive health.

5.1

Nutrition: is there one “longevity diet”?

Sustainable quality, adequacy and personal fit matter more than one perfect diet.

There is no single longevity diet for everyone. The strongest common foundation is a Mediterranean-style pattern emphasising minimally processed foods such as vegetables, fruit, legumes, whole grains, nuts, olive oil and fish. Fibre and plant diversity contribute to gut health, glucose control and satiety. Protein requirements vary with age, activity, kidney health and goals; total intake and its distribution across the day may become particularly important for preserving muscle during weight loss.

Carbohydrates should be assessed not only by grams but by their source, and fats not only by proportion but by type. Time-restricted eating may help some people establish a routine, but late eating, medicines and individual tolerance must be considered. There is no dose of alcohol that is necessary for health; reducing ultra-processed foods is a more effective starting point for many people. The plan is personalised with attention to culture, budget, illnesses and sustainability.

5.2

Muscle: an active organ in healthy ageing

Muscle matters not only for movement, but also for metabolic health, fall prevention and independence.

Muscle mass and strength may gradually decline after early adulthood; inactivity, illness, inadequate nutrition and rapid weight loss accelerate this process. Sarcopenia is a clinical condition involving a reduction not only in muscle quantity but also in strength and physical performance. Muscle tissue plays a role in glucose utilisation, balance and transferring load to bone.

The World Health Organization recommends strengthening activities involving the major muscle groups on at least two days per week for adults. Starting fitness, joint problems and cardiovascular risk affect the programme. Resistance exercise, adequate protein and recovery should be considered together. During weight loss, the aim is not only to reduce the number on the scales, but to preserve muscle strength and function as much as possible; progress is therefore also monitored through load, repetitions and performance.

5.3

Heart and lung capacity

Aerobic capacity is a strong functional indicator reflecting everyday endurance and long-term health.

VO₂max reflects the body's capacity to use oxygen during exercise. Activities performed at a conversational pace that develop the aerobic base help a person accumulate regular time in an appropriate intensity zone. Higher-intensity intervals may offer additional benefits, but should not become a standard programme without assessing starting capacity, illnesses and injury risk.

Daily step count is a practical way to track movement, but does not explain strength, intensity or prolonged sitting on its own. The World Health Organization recommends 150–300 minutes of moderate-intensity or 75–150 minutes of vigorous-intensity aerobic activity per week for adults, plus muscle strengthening on at least two days. Breaking up sedentary time and starting with small increases are valuable. The programme should progress according to the individual's symptoms, goals and recovery.

5.4

Metabolic health

Blood glucose, fat distribution, liver health and muscle capacity together determine metabolic risk.

Insulin resistance means that tissues respond less to insulin signalling, so the body needs more insulin to manage glucose. While fasting glucose may appear normal, post-meal values, triglycerides, waist circumference or fatty liver may point to risk. The focus is therefore on the clinical pattern and change over time, rather than a single laboratory result.

Intra-abdominal visceral fat and fatty liver are associated with cardiometabolic risk. Metabolic flexibility describes the capacity to switch appropriately between energy sources; in everyday practice it is not a single device score. Weight loss may be helpful, but changes in waist circumference, blood pressure, glucose, lipids, liver indicators, strength and mobility are at least as important as the scales.

5.5

Sleep and circadian rhythm

Sleep duration, regularity and quality are part of metabolic, mental and cardiovascular health.

For most adults, regularly getting around 7–9 hours of sleep is an appropriate goal; individual needs may vary. We assess quality not just by hours, but by falling asleep, awakenings during the night, waking refreshed and daytime function. Loud snoring, pauses in breathing, morning headaches or pronounced daytime sleepiness may warrant assessment for sleep apnoea.

Morning and evening light, mealtimes and exercise timing affect the body clock. Smartwatches may help track trends, but their sleep-stage estimates do not replace clinical tests. Rest means taking a passive break; recovery means regaining capacity through sleep, nutrition and appropriate management of physical load. The American Heart Association recognises sleep as a core component of cardiovascular health alongside nutrition, movement, nicotine exposure, blood pressure, blood glucose, cholesterol and body weight.

5.6

Brain health

Brain health is closely related to vascular health, hearing, movement, sleep and social life.

Occasionally forgetting a name or taking time to recall a word is not, by itself, a disease. A marked change in everyday function, difficulty finding one's way, repeatedly asking the same question, personality changes or rapid deterioration do require assessment. The heart and brain share the same vascular system; areas such as blood pressure, diabetes, tobacco, movement and sleep are also related to cognitive health.

Regular exercise, adequate sleep, management of metabolic risks, addressing hearing and vision problems, and social interaction are practical components of brain health. Cognitive tests can provide a baseline; when repeated, familiarity with the questions may produce a “learning effect”. Early assessment is important for identifying treatable causes and establishing a follow-up plan suited to the individual.

5.7

Stress, psychological resilience and social connections

Recovery is not only physical; it also relates to psychological safety, purpose and social connections.

Short-term stress can help us adapt; chronic, uncontrollable stress can negatively affect sleep, blood pressure, appetite, pain and health behaviours. The autonomic nervous system regulates the balance between arousal and rest throughout the day. A single heart rate variability value does not measure all aspects of stress; symptoms and the context of a person's life are more important.

Loneliness and social isolation are not solely emotional issues; they are also related to health. Reliable relationships, a sense of purpose and the ability to ask for help support resilience. Breathing, meditation and relaxation practices may reduce the stress response in some people; they do not replace professional help for severe anxiety or depression. Small, sustainable practices suited to the person are the most useful starting point.

5.8

Exposures that accelerate ageing

Tobacco, alcohol, air pollution, sunlight and environmental factors affect the overall burden on health.

Smoking and other inhaled nicotine products are major causes of preventable disease burden. The risks of alcohol consumption vary with the amount and the individual; starting to drink for health benefits is not recommended. Air pollution and noise can affect cardiovascular and sleep health. Sun protection is a fundamental part of reducing the risk of skin cancer and photoageing.

Exposure to microplastics and some environmental chemicals is widespread, but the individual risk from specific products and effective interventions are not always clear. Reasonable exposure reduction is possible; unproven “detox” packages do not provide reliable clinical evidence of removing toxins from the body and may sometimes cause harm. The priority is to reduce risks for which the effect is well established and action is feasible.

↑ Back to the chapters
CHAPTER 6

Preventive Healthcare and Personalisation

Your needs change with age, family history, existing illnesses and stage of life. Screening and preventive steps are selected according to individual risk. An assessment suited to you matters more than the same check-up package for everyone.

Preventive healthcare is shaped around you.

  • Age and stage of life
  • Family history
  • Current health

An assessment suited to you

Screening and preventive steps are chosen according to individual risk. Personal assessment matters more than the same check-up package for everyone.

More tests do not automatically mean better health. Preventive healthcare means selecting the assessment whose result will genuinely change a decision, for the right person at the right time.

6.1

Is the same check-up right for everyone?

Screening is selected according to age, biological sex, family history and individual risk.

The aim of screening is to detect an asymptomatic problem at a stage when finding it early will provide benefit. Age, biological sex, family history, past illnesses and exposures affect which tests are meaningful. Applying the same broad panel to everyone can lead to false-positive results, unnecessary imaging or biopsies, anxiety and cost.

When choosing a screening test, ask: “What will we do if the result changes?” International sources such as the USPSTF provide a useful framework, but current recommendations from the Ministry of Health and relevant specialist societies should also be considered for practice in Türkiye. Preventive healthcare is not about increasing the number of tests, but matching the balance of benefit and harm to individual risk.

6.2

Longevity at different stages of life

Priorities change with age; risk and function matter more than rigid age cut-offs.

Between the ages of 35–45, the aim is to identify family history, blood pressure, metabolic risk and lifestyle habits early. Between 45–55, changes in body composition, muscle loss, sleep and cardiometabolic health may become more apparent. Between 55–65, building strength, balance and aerobic capacity comes to the fore; after 65, priorities include reducing falls and preserving brain health and independence.

These ranges are not absolute boundaries. During perimenopause and menopause, bone, muscle, sleep, metabolism and symptoms are considered together. In men, cardiovascular, metabolic, prostate and hormone-related issues with advancing age are addressed in the context of individual risk. A good plan uses chronological age as a starting point and bases decisions on the person's current capacity and goals.

↑ Back to the chapters
CHAPTER 7

Supplements and New Longevity Interventions

An approach being biologically interesting does not mean that its benefit in humans has been proven. Distinguish need, clinical outcomes, safety and uncertainties from one another.

Putting evidence in the right category

Putting evidence in the right categoryEstablished: clinical benefit is supported for a particular use. Emerging: human data exist, but outcomes or long-term knowledge are limited. Experimental: effectiveness or safety has not yet been adequately demonstrated. In each category, ask: for whom, for what purpose, and for which outcome?✓ EstablishedClinical benefit for a specific use◐ EmergingHuman data exist; knowledge is limited◇ ExperimentalEffectiveness or safety is uncertainFor whom, for what purpose, for which outcome?
A label is not assigned to an entire product family. Evidence for the same approach may differ across uses.
Text description of the visual

Established: clinical benefit is supported for a particular use. Emerging: human data exist, but outcomes or long-term knowledge are limited. Experimental: effectiveness or safety has not yet been adequately demonstrated. In each category, ask: for whom, for what purpose, and for which outcome?

Source review for this section · 18 October 2026

Ageing research examines not a single “youth molecule”, but different biological processes: cellular energy metabolism, recycling damaged structures, mitochondrial quality and the effects of senescent cells on tissues. In the sections below, we distinguish what each approach targets, what human studies show and which questions remain unanswered. Supplements, prescription medicines and experimental interventions are not the same thing. An improvement in a biomarker does not, by itself, show that a person has become younger or that their lifespan has increased.

NAD metabolism

NR · Nicotinamide riboside · NMN · Nicotinamide mononucleotide
2 topics

NR · Nicotinamide riboside

A precursor used to produce NAD+. Human results should be interpreted in the context of the health condition studied.Human studies exist · Walking distance in peripheral artery disease; not evidence of general rejuvenation.
What is the mechanism?
NAD+ is a helper molecule used in cellular energy production and repair processes. NR is one of the precursors the body uses in its NAD+ production pathways.
What has been observed in humans?
The NICE randomised trial found a promising result for walking distance in people with peripheral artery disease. The study included 90 people and lasted six months.
Limits of the evidence
This finding in a specific disease group does not mean that everyone will experience increased energy, weight loss or rejuvenation. Results for an orally administered precursor cannot be directly transferred to intravenous NAD+ administration.
Safety note
Long-term benefit and safety data are limited. A research finding does not replace a decision about whether use is appropriate for an individual.

NMN · Nicotinamide mononucleotide

Another NAD+ precursor. A metabolic finding in a particular group does not establish the same result for everyone.Human studies exist · Muscle responsiveness to insulin in some postmenopausal women with prediabetes.
What is the mechanism?
NMN is one of the precursors the body uses in its NAD+ production pathways. NAD+ has a role in cellular energy metabolism and repair processes.
What has been observed in humans?
A 10-week study involving 25 women found improved muscle responsiveness to insulin in some postmenopausal women with prediabetes.
Limits of the evidence
The result in this narrowly defined population does not mean increased energy, weight loss or rejuvenation for everyone. NR and NMN results should not be directly transferred to one another, nor should results for oral precursors be directly transferred to intravenous NAD+ administration.
Safety note
Long-term benefit and safety data are limited. A short study does not establish that prolonged use is safe for everyone.

Cellular clean-up and mitochondria

Senolytics and fisetin · Spermidine · Intracellular recycling · Urolithin A · Mitochondrial quality control · Rapamycin · Targeting the mTOR pathway
4 topics

Cellular senescence

Senolytics and fisetin
The idea of targeting senescent cells. The mechanism should be distinguished from clinical benefit demonstrated in humans.Early research · Mainly cell and animal data; senolytic effectiveness has not yet been demonstrated in humans.
What is the mechanism?
Senolytics are based on the idea of selectively targeting senescent cells, whose accumulation can cause problems in some tissues. Fisetin is a plant flavonoid being investigated for this purpose.
What has been observed in humans?
Mouse experiments have reported favourable effects on markers of cellular senescence, healthspan and lifespan. A small human study examining fisetin and exercise reported noteworthy findings for metabolic and inflammatory markers.
Limits of the evidence
This human study did not measure senolytic effects or epigenetic age. It is not appropriate to attribute the combined result of exercise and fisetin to fisetin alone. It does not demonstrate that senescent cells have been cleared in humans or that life has been extended.
Safety note
Being “natural” does not mean that use in high amounts or over long periods is risk-free. Stronger data are needed on clinical benefit and safety.

Autophagy and mitophagy

Spermidine · Intracellular recycling
A natural polyamine linked to autophagy. The SmartAge memory trial did not find superiority to placebo.Effectiveness in humans is unclear · Strong mechanistic research; no superiority to placebo in the SmartAge trial.
What is the mechanism?
Spermidine is a natural polyamine found in cells and some foods. It is studied for its relationship with autophagy, the recycling of worn cellular structures. Cell and animal studies have shown effects through this pathway that may support healthy ageing.
What has been observed in humans?
In the 12-month SmartAge trial involving 100 people, the spermidine-containing extract used was not superior to placebo for memory or the biomarkers examined.
Limits of the evidence
A mechanism seen in cell and animal studies does not mean the same effect has been demonstrated in humans. Spermidine should not be presented as a proven memory enhancer or rejuvenating agent.
Safety note
Long-term supplement safety needs separate assessment. The presence of a substance in food does not mean that every use of it as a supplement is equivalent.
Urolithin A · Mitochondrial quality control
A metabolite prominent in mitophagy research. Some measurements are favourable, but not all outcomes point in the same direction.Human data exist · Some measures of muscle endurance and biomarkers; not evidence of life extension.
What is the mechanism?
Urolithin A is a metabolite that can form when gut microorganisms convert ellagitannins found in foods such as pomegranates; not everyone produces the same amount. It is notable for its relationship with mitophagy, the selective recycling of damaged mitochondria.
What has been observed in humans?
Human studies have found favourable changes in some measures of muscle endurance and blood markers related to mitochondria. A four-month study included 66 people, while the newer MitoImmune study included 50 people with four weeks of follow-up.
Limits of the evidence
Walking distance and ATP production, the primary outcomes of one study, did not differ significantly from placebo. Cellular findings from newer immune research are not evidence of infection prevention or life extension.
Safety note
Good tolerability in short-term studies does not guarantee long-term safety for everyone.

Medicine focus · mTOR

Rapamycin · Targeting the mTOR pathway
A prescription medicine. It is being studied for healthy ageing; it is not a “longevity supplement”.Prescription medicine · under investigation · Effectiveness in humans and the benefit–risk balance for healthy ageing have not been established.
What is the mechanism?
Rapamycin inhibits the mTOR pathway, which regulates cellular growth and nutrient signals. It is a prominent molecule in animal lifespan research; human outcomes are more complex.
What has been observed in humans?
In the PEARL study, some secondary measurements showed favourable signals, but there was no difference in the primary outcome of visceral fat. In another randomised study in 2026, adding it to exercise did not improve functional gains and increased the burden of adverse effects.
Limits of the evidence
Secondary outcomes or animal lifespan findings are not evidence of rejuvenation or life extension in healthy humans. It should therefore not be presented as a “longevity supplement”.
Safety note
Risks such as infection, mouth ulcers, lipid changes and impaired wound healing require an individual benefit–risk assessment and medical follow-up.

Peptides and incretins

CJC-1295 + Ipamorelin · BPC-157 and TB-500 · MOTS-c · GHK-Cu · Epitalon / Epithalon · Semaglutide · GLP-1 · Tirzepatide · GIP/GLP-1 · Retatrutide · GIP/GLP-1/glucagon
8 topics

“Peptide” describes the structure of a molecule; it does not establish that the molecule is effective, safe or rejuvenating. Growth hormone secretagogues, experimental mitochondria-derived peptides and GLP-1-based metabolic medicines do not belong to the same treatment group. GLP-1/GIP/glucagon refers to triple agonists targeting different metabolic receptors.

CJC-1295 + Ipamorelin

Two separate research peptides. Discussing them under one heading does not mean that the effectiveness of the combination has been established.CJC-1295 · Short-term human research · Hormonal outcomes such as GH and IGF-1; not a clinical rejuvenation outcome.Ipamorelin · Human research exists · Research on bowel recovery after surgery; longevity effectiveness has not been demonstrated.
What is the mechanism?
CJC-1295 targets the GHRH pathway, which stimulates growth hormone secretion. Ipamorelin is a research peptide that can stimulate growth hormone secretion through the ghrelin receptor.
What has been observed in humans?
CJC-1295: Short-term studies in healthy adults showed that it could raise GH and IGF-1 levels. Ipamorelin: A phase 2 study after bowel surgery did not find significant superiority for the targeted outcome of bowel recovery.
Limits of the evidence
These are studies of separate molecules in different contexts; they are not evidence of effectiveness when used together. An increase in hormones does not mean a longer life or better everyday function. Postoperative research cannot establish muscle preservation or rejuvenation in healthy people.
Safety note
Long-term benefits and safety for longevity purposes have not been established through strong human data. Safety cannot be assessed independently of the route of use or the patient group studied. For experimental peptides, purity, manufacturing quality, immune responses and risks associated with the route of administration also matter. Long-term safety cannot be inferred from a proposed mechanism alone.

BPC-157 and TB-500

Although both are discussed in relation to tissue repair, their evidence differs. The TB-500 fragment is not full-length thymosin beta-4.BPC-157 · Limited early human data · A small number of small, short-term studies; not established clinical effectiveness or long-term safety.TB-500 · Clinical administration data have not been demonstrated · FDA 2026 fragment assessment; research on full-length thymosin beta-4 cannot be transferred to this fragment.
What is the mechanism?
BPC-157 is being investigated for its effects on pathways associated with tissue repair and inflammation. The thymosin beta-4 fragment known as TB-500 is also discussed in the context of tissue repair; it is not the same molecule as full-length thymosin beta-4.
What has been observed in humans?
BPC-157: Findings are predominantly experimental; a small number of small, short-term human studies also exist. TB-500: The FDA’s 2026 assessment did not identify data on administration of this fragment in humans.
Limits of the evidence
Early BPC-157 research does not establish clinical effectiveness in muscle–tendon healing. Research on full-length thymosin beta-4 cannot be directly transferred to TB-500. Neither is a proven intervention for healthy ageing, reducing biological age or extending lifespan.
Safety note
Small BPC-157 studies do not establish long-term safety; for TB-500, the absence of administration data does not mean that safety has been demonstrated. For experimental peptides, purity, manufacturing quality, immune responses and risks associated with the route of administration also matter. Long-term safety cannot be inferred from a proposed mechanism alone.

MOTS-c

A mitochondria-derived peptide. Changes in its level within the body with exercise are not evidence of benefit from external administration.Animal administration data · Endogenous measurements in humans; clinical benefit from external administration has not been demonstrated.
What is the mechanism?
MOTS-c is a mitochondrially encoded peptide associated with energy metabolism.
What has been observed in humans?
Experimental administration in mice has produced interesting findings for physical capacity and age-related functional changes. Human research has examined changes in the body’s own MOTS-c levels after exercise.
Limits of the evidence
A change in a person’s own MOTS-c level does not show that externally administered MOTS-c is beneficial. These two findings must be distinguished.
Safety note
Long-term clinical benefit, safety and effects on healthy ageing in humans have not yet been adequately established. For experimental peptides, purity, manufacturing quality, immune responses and risks associated with the route of administration also matter. Long-term safety cannot be inferred from a proposed mechanism alone.

GHK-Cu

A copper-binding peptide. Tissue and skin research is not the same as evidence of systemic rejuvenation.Mechanistic and experimental data · Tissue repair; not evidence for systemic longevity.
What is the mechanism?
GHK-Cu is a copper-binding peptide being studied in relation to connective tissue and wound repair processes.
What has been observed in humans?
Experimental studies have observed effects on collagen and the extracellular matrix. These findings are not outcomes of whole-body rejuvenation or increased lifespan.
Limits of the evidence
Use in skincare is not the same as systemic administration by injection or a claim of whole-body rejuvenation. It should not be described as a treatment proven to reduce biological age or extend lifespan.
Safety note
When the route of use changes, the assessment of evidence and safety also changes. For experimental peptides, purity, manufacturing quality, immune responses and risks associated with the route of administration also matter. Long-term safety cannot be inferred from a proposed mechanism alone.

Epitalon / Epithalon

Being studied through telomere biology. An experiment in human cells is not a clinical study involving administration to people.Cell research · Clinical rejuvenation or longevity benefit has not been demonstrated.
What is the mechanism?
Epitalon is a peptide being studied for its effects on telomere and telomerase biology.
What has been observed in humans?
Laboratory experiments using human cells exist; this does not mean clinical studies in which it was administered to people.
Limits of the evidence
A change in telomere length does not, by itself, establish a healthier or longer life. It should not be presented as “rejuvenating by lengthening telomeres”.
Safety note
Effects on these pathways, which are linked to cell proliferation and cancer biology, need careful assessment. Long-term clinical benefit and safety in healthy people have not been demonstrated.

GLP-1-based therapies: single, dual and triple agonists

These three categories differ in their target receptors and research status. Results from separate studies do not provide a direct ranking of superiority; the cards do not recommend doses or individual medicine choices.

Semaglutide · GLP-1
Target: GLP-1Strong clinical data exist for specific indications. This does not mean a rejuvenation treatment for every healthy person.Strong clinical evidence for specific indications · Weight management and cardiovascular outcomes in the patient groups studied; not a general anti-ageing claim.
What is the mechanism?
GLP-1 receptor agonists target metabolic processes such as appetite and glucose regulation.
What has been observed in humans?
Medicines such as semaglutide have strong human research supporting weight management and cardiovascular outcomes in specific patient groups.
Limits of the evidence
The evidence depends on the patient group studied and the clinical outcome. These medicines are not a “rejuvenation treatment” for every healthy person. Exploratory analyses of biological age are explained separately in the shared measurement box.
Safety note
Who may benefit is determined by assessing diseases, nutrition, muscle preservation, adverse effects and follow-up needs together.
Tirzepatide · GIP/GLP-1
Target: GIP + GLP-1Targets two metabolic receptors together. Weight loss alone is not muscle preservation or biological rejuvenation.Strong clinical evidence for weight management · Obesity research; separate clinical outcomes are needed for longevity.
What is the mechanism?
Tirzepatide is a metabolic medicine that targets both GIP and GLP-1 receptors.
What has been observed in humans?
Large human studies have demonstrated effectiveness for weight loss in obesity treatment.
Limits of the evidence
Weight loss alone does not mean that muscle has been preserved or biological age reversed. Separate outcomes are required for longevity.
Safety note
Waist circumference, metabolic health, nutritional adequacy, physical function and sustainability also matter in the assessment. Medicine selection requires an individual assessment.
Sources for this card
Retatrutide · GIP/GLP-1/glucagon
Target: GIP + GLP-1 + glucagonAn investigational medicine targeting three metabolic receptors. Promising results are not approval for routine use.Late-stage clinical research · Obesity research; not the same status as approved options.
What is the mechanism?
Retatrutide is an investigational medicine that targets GIP, GLP-1 and glucagon receptors together.
What has been observed in humans?
It is being evaluated in late-stage clinical studies in obesity. Promising weight-loss results have been reported.
Limits of the evidence
Weight-loss findings are not approval for routine use or evidence of biological rejuvenation. As of October 2026, FDA sources do not list retatrutide as an approved drug ingredient. This US information cannot be used in place of its authorisation status in Türkiye.
Safety note
Long-term safety, patient selection and clinical outcomes also need assessment; an investigational medicine should not be presented as having the same status as approved options.

Advanced and regenerative approaches

Stem cell-based treatments · Muse cells · Exosomes and extracellular vesicles · Therapeutic plasma exchange · TPE
4 topics

Cellular products and medical procedures are not a single “regenerative treatment”. The product used, the disease targeted, the outcome studied and safety are evaluated separately. This section is educational content, not a service or treatment recommendation. FDA information refers to the US regulatory situation; it does not replace information on authorisation in Türkiye.

Stem cell-based treatments

Use of specific products for specific diseases does not mean that healthy people are being rejuvenated.FDA approval for a specific product and disease · Ryoncil in the US for a steroid-refractory transplant complication in children; this cannot be generalised to all cellular therapies.Not proven for general rejuvenation · Disease-specific clinical use differs from a longevity claim in healthy people.
What is the mechanism?
Stem cell therapies are not a single procedure. The source and manufacture of the cells and the disease targeted determine the outcome.
What has been observed in humans?
Some cellular therapies have established or approved uses for specific diseases. For example, a particular mesenchymal stromal cell product has received FDA approval for a steroid-refractory transplant complication in children.
Limits of the evidence
Approval of a particular product for a particular disease does not mean that the same cells rejuvenate healthy people. For longevity, alongside changes in biomarkers, it matters whether function and quality of life improve sustainably.
Safety note
Safety issues such as product quality, infection and immune responses are assessed separately. Different cellular products should not be assumed to be equivalent.

Muse cells

Their potential response to damaged tissue is being investigated. A small stroke study is not a general longevity outcome.Early disease-specific human studies · CL2020 research after stroke; not evidence of rejuvenation in healthy people.
What is the mechanism?
Muse cells are a group of cells identified in adult tissues and studied for their resilience under stressful conditions. Their potential to migrate towards damaged tissues and contribute to repair is of interest.
What has been observed in humans?
A small placebo-controlled CL2020 study involving 35 patients after stroke showed a promising signal towards functional improvement. In the study, 25 people received CL2020 and 10 received placebo.
Limits of the evidence
The study assessed recovery after stroke, not ageing in general. The findings do not show that all Muse products are equivalent or that rejuvenation in healthy people has been proven. Larger and longer studies are needed.
Safety note
A serious treatment-related seizure event was also reported in the study. A small clinical signal does not show that a product is safe under all circumstances.

Exosomes and extracellular vesicles

Structures that carry messages between cells. Differences in manufacturing, contents and products affect clinical outcomes.Preclinical and limited human data · Product- and disease-specific; a general rejuvenating effect has not been confirmed.
What is the mechanism?
Exosomes are one type of small package through which cells carry proteins and other biological messages to one another. In regenerative medicine, they are being investigated for their potential to affect communication between cells and tissue responses. The terms exosome and extracellular vesicle are not exact synonyms.
What has been observed in humans?
Human studies remain limited. A small controlled study in knee osteoarthritis examining extracellular vesicles from placenta-derived mesenchymal stromal cells did not demonstrate superiority over placebo.
Limits of the evidence
Because the source cells, manufacture and contents differ, the name “exosome” alone does not define effectiveness. Results for one product cannot be generalised to all products; tissue regeneration or a reduction in biological age cannot be guaranteed.
Safety note
Purity, sterility and long-term safety must be evaluated alongside effectiveness. FDA product warnings should not be used as a substitute for authorisation status in Türkiye.

Therapeutic plasma exchange · TPE

A medical procedure used for specific diseases. Epigenetic clock findings do not prove clinical rejuvenation.Early controlled human biomarker data · Clinical longevity benefits are not proven; the strongest signal was in the group receiving combination treatment.
What is the mechanism?
TPE is a medical procedure used for specific diseases that involves separating the liquid part of the blood and replacing it with an appropriate fluid. Ageing research examines its potential to change the circulating molecular environment.
What has been observed in humans?
A small controlled human study published in 2025 reported favourable changes in some epigenetic age indicators. The study was completed by 42 people. The most pronounced results were in the group receiving TPE together with another treatment called IVIG.
Limits of the evidence
We cannot attribute the effect to plasma exchange alone. Biomarker findings in small groups do not prove that life is extended or organs are rejuvenated; independent replication and clinical outcomes are needed.
Safety note
The risks of the procedure and its long-term clinical benefit must be evaluated separately from a biological age score. Adverse effects leading to withdrawal were also reported in the study.

Gene addition approaches · The research horizon

Klotho (KL) · Follistatin (FST) · PGC-1α (PPARGC1A) · TERT · A component of telomerase under investigation
4 topics

Gene addition approaches aim to make cells produce particular proteins or change their level of production. These are not more powerful versions of supplements; the duration of their effects, controllability and long-term safety raise different questions. A gene showing favourable results in animals does not mean it is a safe and effective rejuvenation treatment in humans. This section explains research, rather than offering routine longevity interventions.

Klotho (KL)

A protein associated with mineral balance and cellular signals. A result in mice does not prove the same effect in humans.Favourable results in animals · Human longevity benefits have not been confirmed; a study registration is not an efficacy result.
What is the mechanism?
Klotho is a protein involved in mineral balance and various cellular signals associated with ageing.
What has been observed in humans?
In a mouse study published in 2025, increasing a particular form of Klotho produced favourable results for lifespan and some physical functions. This does not prove the same effect in humans.
Limits of the evidence
Registration of human studies alone does not constitute an efficacy result or treatment approval. Animal findings should not be presented as confirmed human longevity benefits.
Safety note
It should not be treated as a routine rejuvenation intervention before long-term benefits and safety have been confirmed in humans.

Follistatin (FST)

A protein associated with signals that limit muscle growth. Findings in a disease group cannot be transferred to healthy people.Early human data in specific muscle diseases · Not proven for general longevity or rejuvenation in healthy people.
What is the mechanism?
Follistatin is a protein associated with signals such as myostatin that limit muscle growth.
What has been observed in humans?
Small early-stage human studies have reported positive signals for walking performance in specific muscle diseases.
Limits of the evidence
Results observed in a disease group are not evidence of increasing muscle, reducing biological age or extending life in healthy people.
Safety note
Long-term safety and genuine functional benefit must be assessed separately from muscle volume.

PGC-1α (PPARGC1A)

Regulates energy production and mitochondrial programmes. Animal data are not a routine human longevity treatment.Predominantly preclinical · Animal findings depend on the tissue and protein form; human longevity benefits have not been demonstrated.
What is the mechanism?
PGC-1α is a helper protein that regulates the cell’s programmes for producing energy and generating mitochondria.
What has been observed in humans?
In animal studies, some forms or approaches to increasing it have produced favourable results for muscle and metabolic function. Routine longevity benefits from gene addition have not been demonstrated in humans.
Limits of the evidence
Results may vary across tissues and protein forms. Findings for a particular isoform cannot be treated as equivalent to PGC-1α biology in general. This is not a routine treatment shown to increase energy, treat sarcopenia or reverse biological age.
Safety note
With gene addition approaches, the duration of the effect, controllability and long-term safety must be assessed separately.

TERT · A component of telomerase under investigation

Telomere maintenance, cell proliferation and cancer biology must be considered together.Preclinical for longevity · Mouse findings; clinical benefit and safe rejuvenation have not been confirmed in humans.
What is the mechanism?
TERT is a component of the enzyme telomerase, which helps maintain the telomeres at the ends of chromosomes.
What has been observed in humans?
Mouse experiments with approaches targeting TERT have reported favourable results for some ageing indicators and lifespan. This has not been proven to be a safe rejuvenation treatment in humans.
Limits of the evidence
The existence of a research registration does not mean a successful human trial. Mouse findings cannot replace confirmed human clinical benefits.
Safety note
Telomere maintenance, cell proliferation and cancer biology must be considered together. The absence of an increase in cancer in animals does not mean that long-term risk has been ruled out in humans.

Being new does not mean an approach is more effective or safer. This section addresses the difference between correcting a deficiency and product-focused “optimisation”, as well as the evidence limits of advanced interventions.

7.1

Are supplements really necessary?

Supplement decisions should take deficiencies, nutrition, illnesses and drug interactions into account together.

A dietary supplement may be used to provide a nutrient that cannot be obtained through food or that laboratory and clinical assessment has shown to be deficient. This approach is not the same as treating a disease. The benefit of vitamin D, B12, omega-3, magnesium or creatine varies according to the person's baseline level, nutrition, age, kidney and liver health, medicines and the outcome being targeted.

Raising a “normal” value as high as possible is not always better. Some supplements can interact with blood thinners, thyroid medicines or other treatments; product contents and quality may also vary. Giving everyone the same package can create unnecessary costs and adverse effects. First identify the need, assess benefits and risks, and, if a supplement is used, reconsider its effects and whether it remains necessary.

7.2

Popular longevity molecules

A biological mechanism, a human study and an actual clinical benefit are not the same thing.

The NAD⁺ precursors NR and NMN, urolithin A, coenzyme Q10, spermidine, fisetin and apigenin are investigated through mechanisms such as cellular energy, autophagy or inflammation. Human studies exist for some of them, but small samples, short durations or intermediate biomarkers prevent firm conclusions about lifespan and long-term clinical benefit. A molecule appearing effective in a cell does not show that it produces a meaningful health outcome in humans.

Rapamycin is a prescription immunosuppressant used for specific medical indications. It is not a routine or standard treatment for longevity; dose recommendations are outside the scope of this guide. When evaluating new candidates, the mechanistic rationale, randomised human data, actual clinical endpoints, long-term safety, product quality and drug interactions should be examined separately. Where uncertainty exists, it should be stated clearly.

7.3

Advanced and regenerative interventions

Hormones, GLP-1 therapies and experimental interventions do not have the same levels of evidence or regulatory approval.

Hormone therapies and GLP-1-based medicines can provide clinical benefit for specific indications with appropriate patient selection and follow-up; they are not general rejuvenation tools. Peptides cannot be considered a single treatment class: each molecule has its own indication, route of administration, product quality and human evidence. A physician should make the treatment decision in conjunction with individual risk, alternatives and applicable regulations.

Exosomes, some cellular products, therapeutic plasma exchange for longevity, rejuvenation and cellular reprogramming approaches are largely in the research or experimental domain. Being biologically interesting does not establish evidence of effectiveness and safety for routine use. Regulatory status, clinical endpoints, adverse effects and long-term follow-up should be sought instead of marketing claims.

7.4

Distinguishing levels of evidence

Established, emerging and experimental approaches cannot be described with the same degree of certainty.

The established-evidence label means that clinical benefit and safety have been adequately demonstrated for a specific indication; the limits of use must still be clear. Emerging evidence means that human data exist, but study duration, sample size, patient selection or endpoints remain limited. The experimental label means that effectiveness or safety is uncertain and the approach is not considered routine care.

These labels are not assigned to an entire product group. The same molecule may have different evidence levels for different diseases, doses or routes of administration. “New” is not a marker of quality. A health decision considers the strength of the evidence, the size of the expected benefit, the likelihood of harm, feasible alternatives and the person's values together.

↑ Back to the chapters
CHAPTER 8

Create Your Own Longevity Roadmap

First understand your starting point, then choose a small number of practical steps. Assess change alongside health and everyday function, not only the scales or a single test. The first 90-day plan is an example of a framework to personalise.

THE FIRST 90 DAYS

Understand your baseline, build a routine, reassess.

  1. Days 0–30Understand your starting point

    Note your everyday function and priorities; complete a health assessment if needed.

  2. Days 31–60Put the steps in place

    Adapt a small number of suitable changes to your daily life.

  3. Days 61–90Assess the change

    What worked, and what could not be sustained? Review the indicators being tracked and the next step together.

This timeline is neither a medical follow-up schedule nor a guarantee of results. Symptoms and your health may require an earlier assessment.

A good roadmap does not change everything at once. It identifies the most important risks and gaps in capacity, selects small but measurable steps, and reassesses the outcome.

8.1

Initial assessment

Your current situation, the most important risks and the measurements to monitor are placed in order of priority.

Five questions are enough to begin: What is my current state of health, what are my three most important risks, which measurements should I actually monitor, which habit should I change first, and which symptoms require professional assessment? Answers are developed alongside history, examination, basic measurements, living circumstances and goals.

Chest pain, unexplained shortness of breath, fainting, new neurological symptoms, significant bleeding, and rapid unintentional weight loss should not be left waiting while following a general lifestyle plan. Priorities vary between individuals. Sometimes the best first step is not an exercise programme, but assessment for sleep apnoea or uncontrolled blood pressure. The plan should make one safe and feasible next step clear.

8.2

A practical plan for the first 90 days

A three-stage plan that follows a cycle of measuring, strengthening the foundations and assessing the outcome.

During the first 30 days, observe basic areas such as sleep, movement, nutrition and blood pressure; complete necessary health assessments and record baseline measurements. During days 31–60, establish a safe resistance-exercise routine, improve nutritional quality, make sleep times more regular, and break up prolonged periods of sitting.

During days 61–90, look at which indicators have actually changed. Assess not only the scales, but also strength, endurance, sleep, waist circumference, blood pressure and everyday function. Change a step that is not working or cannot be sustained; set a small number of measurable goals for the next three months. This timeline is not a medical treatment plan, but a framework for organising personal assessment.

  1. Days 0–30

    Understand your starting point

    • Note your everyday function and priorities; complete a health assessment if needed.
  2. Days 31–60

    Put practical steps in place

    • Adapt a small number of suitable changes to your daily life.
  3. Days 61–90

    Assess the change

    • What worked, and what could not be sustained? Review the indicators being tracked and the next step together.

This timeline is neither a medical follow-up schedule nor a guarantee of results. Symptoms and your health may require an earlier assessment.

8.3

Key indicators to monitor

Progress is monitored alongside laboratory results, body composition, strength, capacity, sleep and quality of life.

Although the monitoring list varies between individuals, waist circumference and body composition, blood pressure, muscle strength, aerobic capacity, and sleep duration and quality are commonly used core indicators. Blood glucose and lipids are assessed at appropriate intervals according to risk. More frequent measurement is not always better; reliability and the effect on decisions matter.

Energy, mobility and quality of life should also be recorded. If laboratory values improve while strength declines or everyday function worsens, the plan is incomplete. Measurements taken with the same method under similar conditions better demonstrate change over time. Progress rests not on a single biological age score, but on changes in health and function together.

↑ Back to the chapters

Longevity Starting Checklist

A starting checklist stored on your own device that does not generate a diagnosis or risk score.

This list is not an exam and does not generate a health score. It helps you see which areas you already monitor and which you may want to discuss with your physician. Your selections are stored only in this device's browser; they are not sent to a server or analytics system.

You can begin by ticking the areas you already know about.

A Final Word

Health management is a cycle of measurement, personalisation and reassessment.

A good start does not mean doing everything at once; it means identifying the risk and area of capacity most meaningful for you today. Strengthen the foundations, track change with reliable measures, and update the plan as your life changes. Seek professional assessment when necessary; examine new and appealing interventions through the lens of evidence and safety.

Longevity is not a treatment; it is an approach to health management that is measured, personalised and developed over time.

YOUR QUESTIONS

Short questions, clear answers.

My blood tests are normal, but I feel tired. Is that possible?

Yes. Assessing fatigue involves more than blood tests. Sleep, the pattern of symptoms, medicines and examination also matter. Seek assessment if fatigue persists or affects everyday life.

Related section and sources →

Does fatigue mean I am ageing quickly?

Not on its own. Fatigue is a symptom whose cause needs assessment. It does not directly establish biological age, mitochondrial dysfunction or a vitamin deficiency.

Related section and sources →

Can the scales alone tell me whether I am losing weight healthily?

The scales show change, but do not explain muscle and fat distribution on their own. Depending on your health, weight can be interpreted alongside waist circumference, strength and other indicators.

Related section and sources →

Does regaining weight mean I lack willpower?

No. Weight management is influenced by biological and environmental factors. When weight is regained, the plan and need for support should be reassessed; blame is not a solution.

Related section and sources →

Is medication essential for losing weight?

No. Medicines are among the options considered for suitable individuals. Whether they are needed is determined through personal assessment; nutrition, movement and follow-up remain important even when medication is used.

Related section and sources →

Do I have to take a biological age test for longevity?

No. A healthy ageing plan does not depend on a single score. Current risks, lifestyle habits and functional assessment matter; the added contribution of a test and its effect on decisions are discussed separately.

Related section and sources →

Is there a longevity supplement package that everyone should use?

A single package for everyone is not the right approach. Needs, current medicines and potential harms must be assessed. Supplements do not replace balanced nutrition or necessary treatment.

Related section and sources →

What result should I expect in the first 90 days?

The same change in weight, energy or biological age cannot be promised to everyone. The initial aim is to understand your starting point, establish practical steps and assess changes that are meaningful for you.

Related section and sources →

References and Medical Information

Selected authoritative sources underpinning the guide, and medical information.

References are linked to individual sections and listed together below. Current guidelines, official health authorities, systematic reviews and robust human studies are prioritised. Because scientific knowledge can change, publication and medical review dates matter.

Complete reference list

Clinical sources and research (88)

  1. WHO guidelines on physical activity and sedentary behaviourWorld Health Organization · 2020 · ISBN 9789240015128
  2. Life’s Essential 8American Heart Association · 2022
  3. A and B RecommendationsU.S. Preventive Services Task Force · 2026
  4. Screening ProgrammesRepublic of Türkiye Ministry of Health, General Directorate of Public Health · 2026
  5. Guide to Diagnosis and Treatment in Older AdultsRepublic of Türkiye Ministry of Health · 2024
  6. Healthy dietWorld Health Organization · 2024
  7. Dietary Supplements: What You Need to KnowNIH Office of Dietary Supplements · 2025
  8. Consumer Alert on Regenerative Medicine ProductsU.S. Food and Drug Administration · 2021
  9. Dementia prevention, intervention, and care: 2024 reportThe Lancet · 2024 · 10.1016/S0140-6736(24)01296-0
  10. 2021 ESC Guidelines on cardiovascular disease preventionEuropean Heart Journal · 2021 · 10.1093/eurheartj/ehab484
  11. 2026 ACC/AHA Guideline on the Management of DyslipidemiaCirculation · 2026 · 10.1161/CIR.0000000000001423
  12. Standards of Care in DiabetesAmerican Diabetes Association · 2026
  13. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminNew England Journal of Medicine · 2002 · 10.1056/NEJMoa012512
  14. Primary Prevention of Cardiovascular Disease with a Mediterranean DietNew England Journal of Medicine · 2018 · 10.1056/NEJMoa1800389
  15. A Clinical Trial of the Effects of Dietary Patterns on Blood PressureNew England Journal of Medicine · 1997 · 10.1056/NEJM199704173361601
  16. Sarcopenia: revised European consensus on definition and diagnosisAge and Ageing · 2019 · 10.1093/ageing/afy169
  17. PROT-AGE Study Group position paperJournal of the American Medical Directors Association · 2013 · 10.1016/j.jamda.2013.05.021
  18. Prognostic value of grip strength: the PURE studyThe Lancet · 2015 · 10.1016/S0140-6736(14)62000-6
  19. Association of Cardiorespiratory Fitness With Long-term MortalityJAMA Network Open · 2018 · 10.1001/jamanetworkopen.2018.3605
  20. Daily steps and all-cause mortality: a meta-analysisThe Lancet Public Health · 2022 · 10.1016/S2468-2667(21)00302-9
  21. Recommended Amount of Sleep for a Healthy AdultJournal of Clinical Sleep Medicine · 2015 · 10.5664/jcsm.4758
  22. Cognitive Health and Older AdultsNational Institute on Aging · 2024
  23. Good night’s sleepNational Institute on Aging · 2024
  24. The 2022 hormone therapy position statementMenopause · 2022 · 10.1097/GME.0000000000002028
  25. Osteoporosis to Prevent Fractures: ScreeningU.S. Preventive Services Task Force · 2025
  26. Exercise for preventing falls in older people living in the communityCochrane Database of Systematic Reviews · 2019 · 10.1002/14651858.CD012424.pub2
  27. Hallmarks of aging: An expanding universeCell · 2023 · 10.1016/j.cell.2022.11.001
  28. Geroscience: linking aging to chronic diseaseThe Journals of Gerontology · 2014 · 10.1093/gerona/glu047
  29. Effect of long-term caloric restriction on DNA methylation measures of biological agingNature Aging · 2023 · 10.1038/s43587-022-00357-y
  30. ISSN position stand: safety and efficacy of creatine supplementationJournal of the International Society of Sports Nutrition · 2017 · 10.1186/s12970-017-0173-z
  31. WHO report on the global tobacco epidemicWorld Health Organization · 2025
  32. AlcoholWorld Health Organization · 2024
  33. Adult Immunization ScheduleCenters for Disease Control and Prevention · 2026
  34. Physical Activity Guidelines for Americans, 2nd editionU.S. Department of Health and Human Services · 2018
  35. Diet, nutrition and the prevention of chronic diseasesWorld Health Organization · 2003 · WHO Technical Report Series 916
  36. Body composition and agingNational Institute on Aging · 2024
  37. Fatigue: when to seek assessment?NHS
  38. ME/CFS: post-exertional worsening and individual assessmentNICE NG206
  39. The clinical context of thyroid testsNICE NG145
  40. Supplements: safety and drug interactionsNIH ODS
  41. Symptoms requiring emergency assessmentLondon Ambulance Service
  42. Assessing weight, BMI and central adiposityNICE NG246
  43. Weight loss and exercise in older adults with obesityNEJM · Villareal et al., 2017
  44. Factors affecting weight and healthNIDDK
  45. Individualised nutrition and physical activityNICE NG246
  46. Long-term weight management and supportNICE NG246
  47. The role of medicines in weight managementNICE NG246
  48. NICE randomised trial · Nature Communications, 2024Guide to molecules and interventions
  49. NMN study in postmenopausal women · Science, 2021Guide to molecules and interventions
  50. Fisetin cell and animal research · EBioMedicine, 2018Guide to molecules and interventions
  51. Fisetin and exercise, a small randomised trial · Nutrients, 2026Guide to molecules and interventions
  52. Research on the mechanism of spermidine · Nature Cell Biology, 2024Guide to molecules and interventions
  53. SmartAge randomised trial · JAMA Network Open, 2022Guide to molecules and interventions
  54. Muscle endurance and mitochondrial measurements · JAMA Network Open, 2022Guide to molecules and interventions
  55. MitoImmune · Nature Aging, 2025Guide to molecules and interventions
  56. PEARL study · Aging, 2025Guide to molecules and interventions
  57. RAPA-EX-01 · Journal of Cachexia, Sarcopenia and Muscle, 2026Guide to molecules and interventions
  58. Official sirolimus product information · DailyMedGuide to molecules and interventions
  59. CJC-1295 · Short-term human researchGuide to molecules and interventions
  60. Ipamorelin · Postoperative phase 2 researchGuide to molecules and interventions
  61. FDA · BPC-157 assessment, 2026Guide to molecules and interventions
  62. Early human research on BPC-157Guide to molecules and interventions
  63. FDA · Research peptide assessment, 2026Guide to molecules and interventions
  64. Research on MOTS-c, exercise and physical capacityGuide to molecules and interventions
  65. Experimental research on GHK-Cu and tissue repairGuide to molecules and interventions
  66. Epitalon and telomere biology · Cell researchGuide to molecules and interventions
  67. Correction record for the publicationGuide to molecules and interventions
  68. Semaglutide and cardiovascular outcomes · NEJMGuide to molecules and interventions
  69. Tirzepatide and obesity · NEJMGuide to molecules and interventions
  70. Retatrutide clinical research · NEJM, 2026Guide to molecules and interventions
  71. FDA · Warnings about unapproved GLP-1 medicinesGuide to molecules and interventions
  72. FDA · Certain compounding substances that may present safety risksGuide to molecules and interventions
  73. FDA · Disease-specific approval for Ryoncil, 18 December 2024Guide to molecules and interventions
  74. Niizuma and colleagues · CL2020 study after stroke, 2023Guide to molecules and interventions
  75. Bolandnazar and colleagues · Controlled EV research in knee osteoarthritis, 2024Guide to molecules and interventions
  76. FDA · Product-related warning letter, 2025Guide to molecules and interventions
  77. Fuentealba and colleagues · Controlled TPE biomarker study, Aging Cell, 2025Guide to molecules and interventions
  78. Study DOI linkGuide to molecules and interventions
  79. Klotho · Lifespan and function research in mice, 2025Guide to molecules and interventions
  80. Full study textGuide to molecules and interventions
  81. Correction record concerning a figure legendGuide to molecules and interventions
  82. Follistatin · Early human research in muscle diseaseGuide to molecules and interventions
  83. Follistatin · Early disease-specific clinical researchGuide to molecules and interventions
  84. Preclinical research on PGC-1α biologyGuide to molecules and interventions
  85. Research on PGC-1α forms and muscle biologyGuide to molecules and interventions
  86. TERT-targeted approach · Ageing and lifespan research in miceGuide to molecules and interventions
  87. Study DOI linkGuide to molecules and interventions
  88. Semaglutide and epigenetic clocks · Exploratory analysis in a specific group, 2026Guide to molecules and interventions

Further reading · Popular science books

These books are for exploring different perspectives; they do not replace clinical guidelines or personal treatment advice.

If you would like to review your health goals and current situation together, you can explore how the assessment process works.

Explore the assessment process →